JAMA Author Interviews: Covering research in medicine, science,& clinical practice. For physicians, researchers,& clinicians.   /     Zerlasiran, a Small-Interfering RNA That Targets Lipoprotein(a)

Description

Elevated lipoprotein(a) levels increase the risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. Cleveland Clinic’s Steven E. Nissen, MD, speaks with JAMA Executive Editor Gregory Curfman, MD, about how zerlasiran produced more than 80% reductions in time-averaged lipoprotein(a) concentration. Related Content: Zerlasiran—A Small-Interfering RNA Targeting Lipoprotein(a)

Subtitle
Elevated lipoprotein(a) levels increase the risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. Cleveland Clinic’s Steven E. Nissen, MD, speaks with JAMA Executive Editor Gregory Curfman, MD, about how zerlasiran produced...
Duration
14:21
Publishing date
2024-11-18 19:40
Link
https://edhub.ama-assn.org/jn-learning/audio-player/10.1001/jama.2024.23752
Contributors
Enclosures
https://traffic.libsyn.com/secure/jamaauthorinterviews/Zerlasiran_a_Small-Interfering_RNA_That_Targets_Lipoproteina.mp3?dest-id=90171
audio/mpeg

Shownotes

Elevated lipoprotein(a) levels increase the risk of atherosclerotic cardiovascular disease (ASCVD) and aortic stenosis. Cleveland Clinic’s Steven E. Nissen, MD, speaks with JAMA Executive Editor Gregory Curfman, MD, about how zerlasiran produced more than 80% reductions in time-averaged lipoprotein(a) concentration. Related Content: